Background: The pancreas is one of the primary organs affected by dysfunction of the cystic fibrosis transmembrane conductance regulator (CFTR) protein. While exocrine pancreatic insufficiency is a well-recognized complication of cystic fibrosis (CF), symptomatic pancreatitis is often under-recognized. Results: The aim of this review is to provide a general overview of CFTR mutation-associated pancreatitis, which affects patients with pancreatic sufficient CF, CFTR-related pancreatitis, and idiopathic pancreatitis. The current hypothesis regarding the role of CFTR dysfunction in the pathogenesis of pancreatitis, and concepts on genotype-phenotype correlations between CFTR and symptomatic pancreatitis will be reviewed.
Introduction
Cystic fibrosis (CF), termed after the autopsy findings of "cystic fibrosis of the pancreas" in malnourished infants [1] , is caused by mutations in the gene that encodes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein [2] . The CFTR protein functions on the apical surface of epithelial cells as a cyclic AMP-dependent chloride channel, a bicarbonate channel and as a modulator of other ion channels [3] [4] [5] [6] [7] [8] . CFTR is located in the apical membrane of secretory and absorptive epithelial cells of the pancreas, intestine, liver, airway, vas deferens and sweat glands. Absence or defective function of the protein product is directly or indirectly responsible for disease pathogenesis in CFaffected organs. The manifestations of CF generally arise when ductal or glandular obstruction occurs due to an inability to hydrate macromolecules within affected ductal lumens.
Functionally, the pancreas can be divided into its exocrine and endocrine components. The former is comprised of pancreatic acinar and ductular cells, while the latter is primarily composed of pancreatic islet cells. Although CFTR is predominantly expressed in the pancreatic ductal epithelium, both exocrine and endocrine components of the pancreas are affected, to varying degrees, in CF. In health, the human pancreatic ductal epithelium secretes large volumes (1-2 L/day) of alkaline fluid made of sodium chloride and bicarbonate, as well as other cations (e.g. potassium) [9, 10] . The pancreatic secretion is physiologically intended to flush digestive enzymes secreted by pancreatic acinar cells down the pancreatic-biliary tree and into the duodenum. The alkaline solution also functions to alkalinize acidic chyme emptied from the stomach into the duodenum, and to provide the optimal pH milieu for pancreatic digestive enzyme activity. In CF disease, exocrine pancreatic damage in its severe form is known as pancreatic insufficiency (PI). Pancreatic damage begins in utero and continues into infancy or early childhood when complete loss of pancreatic acinar tissue occurs [11, 12] . Only 1-2% of residual pancreatic reserve is required to maintain pancreatic sufficiency (PS). In contrast to PI CF, patients with PS CF have sufficient exocrine pancreatic function to maintain normal nutrient digestion without the use of pancreatic enzyme supplements. In CF, pancreatic secretions have lower fluid volumes and increased acidity within the pancreatic lumen which leads to precipitation of the protein rich secretions, causing plugging of small ducts, obstruction, and progressive damage to the pancreas (Fig. 1) . Despite the progressive destruction of the acinar pancreas by inflammation and fibrosis the vast majority of PI individuals have no clinical manifestations of pancreatitis in early life.
Among all the different organ systems affected, the exocrine pancreas is the most reliable phenotypic barometer of CFTR function [13, 14] . Most CF patients carrying functionally severe mutations on both alleles have a PI phenotype [13] [14] [15] [16] . A small proportion of patients carrying severe mutations on both alleles are PS at diagnosis, but most progressively transition from PS to PI state. Patients who carry a mild mutation on at least one allele, which confers some residual ion channel function, usually have sufficient exocrine pancreatic function to allow normal digestion of nutrients. Thus, mutations that confer the pancreatic sufficient phenotype do so in a dominant fashion. PS CF patients are often diagnosed at an older age, notably in adolescence and adulthood and present with more subtle disease manifestations and lower sweat chloride concentrations than PI CF patients [14, 17] .
Pancreatitis in CF and CFTR-related disorder
Symptomatic pancreatitis is a well known but uncommon manifestation in CF disease because it occurs exclusively in PS CF patients and not in patients with PI CF [15, 16, 18, 19] . This is not surprising since the presence of a "critical mass" of pancreatic acinar tissue is necessary for symptomatic pancreatitis to occur and considering that the majority of CF patients (85-90%) who carry functionally severe CFTR mutations on both alleles have PI. Therefore, the vast majority of individuals with severe mutations on both alleles do not develop symptomatic pancreatitis. Approximately, 20% of PS CF patients develop pancreatitis, while the rest do not [15, 16, 19] .
In addition, to PS CF patients, individuals with so-called "idiopathic" recurrent-acute or chronic pancreatitis have an increased incidence of mutations in the CFTR gene [20] [21] [22] . Bishop et al. reported that 43% and 11% of patients with idiopathic recurrent-acute or chronic pancreatitis carried at least one, and two CFTR mutations (and/or variants), respectively [22] . On thorough evaluation with sweat test, genotyping and nasal potential difference testing, the diagnostic criteria of CF could be fulfilled in 21% of these patients. The remaining individuals who did not fulfill the diagnostic criteria for CF but have evidence of CFTR dysfunction on sweat chloride and/or NPD testing but insufficient dysfunction to diagnose CF (e.g. sweat chloride values in the intermediate range) may be diagnosed as having a CFTRrelated disorder.
Pathogenesis
There are complex interactions between the ductular and acinar components of the pancreas in the development of pancreatitis. Each component is further influenced by various genetic and environmental factors. While an obstructive tubulopathy of the pancreas due to the CFTR dysfunction is thought to be the primary initiating factor, the exact pathogenic process of pancreatitis associated with CFTR mutations is still under investigation.
Recent studies suggest an important role of CFTR in the development of pancreatitis, particularly through its role in intraluminal pH regulation from bicarbonate (alkaline) secretion and the flushing of ductal proteins. Secretory granules of pancreatic acinar cells co-release protons (H + ) with digestive enzymes during normal pancreatic secretion [23] . Diminished ductal bicarbonate secretion and consequent reduced alkalinization of the acinar lumen may promote the development of pancreatitis since acidification of the pancreatic lumen can lead to a loss of tight junction integrity, allowing the leakage of digestive enzymes into the pancreatic duct lumen and interstitial space. Decrease in pH within the ductal lumen is also associated with acceleration of trypsinogen autoactivation into trypsin, initiating the early stages of autodigestion of the pancreas by pancreatic enzymes. The presence of active trypsin in the pancreatic duct lumen may lead to additional reduction in bicarbonate secretion due to inhibition of CFTR and other luminal anion exchangers (e.g. SLC26) via proteinase-activated receptor 2 [24] . Further reduction in bicarbonate secretion by the ductal epithelium generates a vicious cycle and environment of falling pH, enhanced trypsinogen activation and decreased intraluminal fluid volume, which promotes the development of pancreatitis.
CFTR mutations
Since the discovery of the CFTR gene in 1989, advances in molecular analysis techniques have identified N1800 CFTR mutations. In this context, the term mutation, simply refers to a molecular alteration in the DNA sequence of a gene, with no inference made regarding the effect of this alteration on gene expression, protein function and, therefore, clinical phenotype. The effect of the mutation on gene expression or function of the protein product is still unknown for many of the CFTR mutations which have been identified. This is especially true for missense mutations which represent approximately 40% of the identified mutations.
A 5-class classification system for CFTR mutations was originally developed to categorize the molecular characteristics of different mutations [25] . On the basis of its molecular defect, mutations in Classes I-III were predicted to have severe functional and phenotypic consequences. Conversely, mutations belonging to Classes IV and V may confer residual CFTR function and thus, be predicted to be associated with milder phenotypic consequences. Remarkably, genotype-phenotype studies of the exocrine pancreatic function status demonstrated an excellent correlation between Classes I-III with a PI phenotype, and Classes IV-V with a PS phenotype [13, 14] . A 6th mutation class has subsequently been proposed which is also associated with severe functional and phenotypic consequences.
Although this 5-class system is useful as a conceptual framework, it has several limitations [19, 26] which include: (i) molecular changes of different mutations within the same class (especially Classes IV and V), may have varying functional consequences, (ii) mutations may have overlapping molecular defects which may be assigned to more than one class, (iii) the molecular consequences of the majority of rare CFTR mutations, particularly missense alterations are unknown or cannot be Table 1 Derivation of the Pancreatic Insufficiency Prevalence (PIP) score, and comparison between PIP and the traditional 5-class system. Adapted from Ooi et al. [19] . The PIP score for a specific mutation is the ratio between the pancreatic insufficient patients carrying the mutation (Total PI) and all pancreatic insufficient and sufficient patients (Total PI + PS) carrying the same mutation in a homozygous state or heterozygous in a combination with a severe mutation such as F508del, G551D or a Class I mutation. For example, a ratio of 1.00 indicates that all patients with 621+1 GN T are PI when associated with a severe mutation on the other allele. Similarly, a ratio of 0.1 demonstrates that 10% of subjects with R334W are PI. Mutations were classified as either "mild" (≤ 0.25; shaded gray) or "severe" (N0.25) on the basis on the PIP score. The PIP scores derived from the Canadian cohort were validated against subjects from the Verona CF Centre. predicted, and (iv) inferred properties of many mutations remain to be confirmed by functional studies. Indeed, the inability to predict functional severity and clinical consequence in the majority of CFTR mutations beyond the traditional 5 class system has limited previous studies in genotype-phenotype correlations in pancreatitis. Since pancreatitis in CF is limited to PS CF patients with residual CFTR function, most pancreatitis affected individuals carry uncommon to rare missense CFTR mutations, which are usually those of uncertain functional consequences (or mutation class).
Total
To address these limitations, we recently developed and validated a novel classification system for mutation severity, known as the Pancreatic Insufficiency Prevalence (PIP) score [19] . Classification by the PIP score is based on several premises: (1) the well-established correlation between severity of CFTR mutations and exocrine pancreatic function, (2) the dominant phenotypic effect conferred by the milder of the two CFTR mutations, and (3) the availability of a comprehensive database containing large numbers of CF patients with stringent clinical diagnosis and exocrine pancreatic status determination. Since the Canadian Consortium for CF Genetic Studies and Verona CF Centre databases fulfilled the latter criterion, we developed derivation and validation cohorts respectively, for the PIP score (Table 1) . Exocrine pancreatic status was determined objectively in all patients and not purely based on unreliable methods such as clinical symptoms suggesting steatorrhoea or the use of pancreatic enzyme replacement therapy. The PIP score for a specific mutation is calculated based on the ratio between PI patients carrying the mutation and all PI and PS patients carrying the same mutation in a homozygous state or heterozygous in a combination with mutations known to have severe consequences, such as F508del or most Class I mutations (Table 1 legend) . A PIP score could only be assigned to patients with identified mutations on both alleles based on the lowest PIP score of the two identified mutations. A PIP score for very rare mutations should be interpreted with caution due to derivation from very small number of subjects. The PIP scores of CFTR mutations identified from subjects in the Canadian Consortium for CF Genetic Studies database are shown in Table 2 .
The PIP scoring system permitted a more refined classification of the functional severity of CFTR mutations (than can be provided by the conventional 5 class system) and in a far greater number of patients than previous method(s) of classification. Thus the scoring system can be applied to other studies and settings. Categorically, mutations can be classified as either mild (≤0.25) or severe (N 0.25) on the basis of the PIP score.
Genotype and phenotype correlations
Several key factors have previously impeded in-depth evaluation of the relationship between CFTR mutations and pancreatitis. Earlier studies which defined the association of CFTR mutations with idiopathic recurrent-acute or chronic pancreatitis used commercially available screening panels of the most common CF-causing mutations, most of which resulted in PI exocrine status rather than mutations commonly found in subjects with PS. Even with the availability of gene sequencing, the inability to predict/classify the functional severity of a large majority of CFTR mutations remains. Furthermore, symptomatic pancreatitis is an uncommon manifestation in CF which occurs almost exclusively in PS CF patients; this makes genotypephenotype correlation studies difficult due to sample size limitations.
These limitations are noteworthy since findings based on previous studies which did not control for the above-mentioned issues have become contentious. For example, an earlier report, suggested that the risk of developing CFTR mutation-associated pancreatitis was greatest in individuals who carried compound heterozygote genotypes containing 1 severe plus 1 mild-variable mutation [27] . Thereafter, it was suggested that CFTR mutationassociated pancreatitis can be divided into 4 subtypes [28] : (1) Type 1 is "classic" CF with two severe alleles; (2) Type 2 is "atypical" CF with compound heterozygosity with a severe and mild-variable mutation; (3) Type 3 is CFTR mutation(s) plus a second susceptibility gene (e.g. SPINK1 as gene modifier); and (4) Type 4 is a compound heterozygote with a severe or mildvariable allele plus a strong environmental modifier factor (e.g. heavy alcohol consumption). In contrast, our own findings suggest that subjects who carry two mild mutations [19] have the highest risk of CF-associated pancreatitis and terminologies of "classic" and "atypical" CF are no longer recommended [29] .
In the largest systematic study to date, involving 277 PS CF subjects with and without pancreatitis, we demonstrated that the risk of pancreatitis was associated with severity of CFTR genotype [19] . This study was designed to address the aforementioned limitations and utilized a study cohort composed only of objectively confirmed PS CF patients with 2 identified CFTR mutations, thereby allowing a more refined focus on CFTR as the primary pathogenic factor and unlike other studies which evaluated subjects based on a prior diagnosis of pancreatitis with or without a control group. Patients with PS CF who developed pancreatitis were more likely to carry mild (PIP score ≤0.25) than severe (PIP score N 0.25) genotypes (Fig. 2A) . In addition, patients carrying mild genotypes had a significantly higher cumulative proportion and 71% increase in risk of developing pancreatitis at any given time (hazard ratio = 2.4) than those with moderatesevere genotypes. Further evidence of an association between the severity of CFTR genotypes and the risk of pancreatitis was observed when patients were sub-stratified according to the severity of each CFTR allele. The presence of mild mutations on both alleles conferred a significantly higher cumulative proportion and greater risk of pancreatitis than those with mild/severe and severe/severe alleles. In fact, there appeared to be a gradation of risk of developing pancreatitis according to genotype severity (Fig. 2B) . At any given time, patients carrying mild mutations on both alleles (mild/mild) had the greatest risk of pancreatitis (hazard ratio = 4.2) which is followed by patients carrying one mild (mild/severe; hazard ratio = 1.9), when compared with those who carried severe mutations on both alleles. This finding was also supported by another recent study reporting R75Q, a mild mutation, being significantly associated with chronic pancreatitis [30] . Although R75Q has been suggested to be a specific pancreatitis-associated mutation due to selective bicarbonate conductance defect, there have been patients not affected by pancreatitis identified with this mutation who presented with other single organ manifestations of CF in adulthood such as chronic sinopulmonary disease [31] .
Other phenotypic differences between PS CF patients with and without pancreatitis supported the contention that, as a group, those at risk of pancreatitis carried milder mutations. Patients with pancreatitis were diagnosed with CF at a significantly older age than those without pancreatitis (median (IQR) ages at diagnosis of 14.9 (9.5-27.7) vs. 9.3 (1.5-21.4); P =0.003). Furthermore, patients with pancreatitis had a significantly lower mean (SD) sweat chloride than patients without pancreatitis (74.5 (26.2) vs. 82.8 (25.2) mmol/L; P = 0.03).
This study provided novel insight into the overall pathogenic role of CFTR in pancreatitis not only in CF but also among those with "idiopathic" pancreatitis associated with CFTR-mutations (Fig. 3) . The findings are consistent with the hypothesis that risk of pancreatitis is related to the balance between degree of pancreatic acinar preservation and severity of pancreatic ductal (and/or ductular) obstruction, both of which are associated with the range of severity of CFTR dysfunction, but in opposing directions. Among subjects who carry sufficient CFTR function to confer PS, there is a risk of pancreatitis when sufficient pancreatic acinar tissue is present for obstructive ductal lesions to cause disease. Based upon this concept, the risk of pancreatitis will increase with milder CFTR dysfunction, correlating with greater pancreatic acinar reserve. At some point, the risk of CFTR-associated pancreatitis lessens when there is sufficient ductal flow to prevent development of obstructive disease necessary for pancreatitis. However, as discussed below, dysfunctional CFTR is only one of a number of other genetic and environmental factors that contribute to the risk of pancreatitis. These other modifying factors also help determine the heterogeneity of end-organ disease (exocrine pancreas, sinopulmonary tract, liver etc.) in all CF affected organs.
Genetic and/or environmental modifiers for CF and CFTR-related pancreatitis
Various CF modifier genes have been identified that influence disease manifestation and severity in CF-affected organs such as lung disease, liver cirrhosis, meconium ileus and CF-related diabetes. The development of pancreatitis among those who carry CFTR mutations is not an exception. Not all PS CF patients who carry mild genotypes develop pancreatitis, as widely observed in clinical practice and confirmed by a recent study [19] , suggesting additional influences on phenotype by non-CFTR modifier factors (genetic and/or environmental) even in a monogenic disease such as CF. For example, the risk for developing recurrent-acute or chronic pancreatitis has been reported to be greater in individuals who carry mutations in both the CFTR and SPINK1 genes [27, 32] . Other genetic factors are likely to play a role but remain to be determined. The interactions with environmental factors such as cigarette smoking, alcohol and diet are highly complex, and are only beginning to unravel.
Clinical characteristics of pancreatitis in CF
Symptomatic pancreatitis in CF remains an under-recognized condition and diagnosis requires a high index of suspicion. It occurs in 20% of PS CF patients, with a quarter presenting with pancreatitis prior to the diagnosis of CF, typically at later childhood and adulthood [19] . Abdominal pain, usually located in the epigastric region, associated with varying degrees of nausea and vomiting are the typical symptoms. There is variation in the agreed "cut-off" value of serum pancreatic enzyme concentrations, among various consensus documents and publications, for confirming the diagnosis of acute pancreatitis [19, 21, 33, 34] . This generally ranges from ≥two times to ≥three times above the upper limit of normal. Imaging evidence of acute inflammation of the pancreas also helps to confirm the diagnosis of acute pancreatitis. Imaging of the pancreas in PI CF patients invariably show chronic changes of pancreatitis (e.g. atrophy, calcification and duct abnormalities) [35] . However, these findings are not necessarily indicative of clinical pancreatitis since there is already significant destruction and loss of exocrine pancreatic tissue.
Prognosis
Based on a large cohort of PS CF with pancreatitis [19] , the majority of affected patients have been reported to develop recurrent-acute pancreatitis (60%); another 20% experienced a single episode of acute pancreatitis and 20% showed progression to chronic pancreatitis. In usual circumstances, PS CF patients who carry mild genotypes are expected to remain PS. However, in the presence of symptomatic pancreatitis, there is an increased risk (odds ratio= 5.5) of PS CF patients developing exocrine pancreatic insufficiency. The progression from PS to PI was reported to occur at least a decade after the first documented episode of pancreatitis.
Pancreatic cancer
Due to the relatively young age of the CF patient population, the absolute risk of malignancy has been low. However, as age of survival of CF patients continues to increase, it has become recognized that there is an increased risk of malignancy in the gastrointestinal and biliary tracts [36] . Interestingly, the risk of malignancy in the pancreas was reported, in a sub-analysis, to be greater than the overall risk of cancer in the digestive tract (odds ratio (95% CI) of 31.5 (4.8-205) vs. 6.4 (2.9-14), respectively). Due to the nature of the study, the exocrine pancreatic status (PI vs. PS) of patients with pancreatic cancer was not reported. Since chronic pancreatitis is a risk factor for pancreatic cancer, we speculate that PI CF patients have the greatest risk due to the early onset (in-utero) of chronic inflammation in the pancreas. Nevertheless, the risk of pancreatic cancer also appears to be raised among non-CF individuals who carry 1 or 2 CFTR mutations. In a prospective study of 949 patients with pancreatic adenocarcinoma, there was a modest increase in risk of pancreatic adenocarcinoma among those who carried CFTR mutation(s) (odds ratio (95% CI) of 1.82 (1.14-2.94)) [37] . Carriers of CFTR mutations were seen to be diagnosed at a younger age than noncarriers, with the effect exclusively seen in ever-smokers, suggesting the additive modifying effects of cigarette smoking.
Areas for future research
Greater insights into underlying molecular mechanisms are much needed. The complex interactions between various genetic and environmental factors that influence disease manifestation and severity remain to be determined. Multicenter collaborations, with careful phenotyping and genotyping of subjects, are necessary for such studies given this relatively uncommon manifestation of CF. Genetic association studies aimed at identifying novel CFTR mutation-associated pancreatitis have potential therapeutic implications, especially in the era of targeted drug design. Currently, there is no specific therapy available for pancreatitis. Given the exciting advances in therapies aimed at improving CFTR [38] , we wonder whether these forms of therapy could be applied to prevent, reduce risk or ameliorate pancreatitis. This is an important consideration given that a large subset of patients with so-called "idiopathic" pancreatitis carries mild CFTR mutations on at least one allele. In addition, the role of genetic tests for disease stratification and prognostication remains to be explored.
Conclusion
There has been a vast expansion in our understanding of the wide range of phenotypes associated with CFTR dysfunction since the discovery of the CFTR gene. Pancreatitis is one such phenotype, which is seen almost exclusively among PS CF patients. The relationship between the severity of CFTR genotypes and the risk of pancreatitis has been established. The genotype-phenotype correlation in pancreatitis is unique compared to other organ manifestations but is still consistent with the complex monogenic nature of CF. Paradoxically, genotypes associated with otherwise mild phenotypic effects have the greater risk for causing pancreatitis; compared with genotypes associated with moderate to severe disease phenotypes. Greater understanding into the underlying mechanisms of disease is much needed. The emergence of CFTR-assist therapies may potentially have a significant therapeutic role in the treatment of all forms of CFTR-mutation associated pancreatitis.
